Neurogene Reports Second Quarter 2024 Financial Results and Highlights Recent Updates
Neurogene Inc. (NGNE)
Company Research
Source: Business Wire
NGN-401 gene therapy for Rett syndrome received RMAT designation from FDA based on preliminary clinical evidence indicating the potential to address unmet medical needsNGN-401 selected for FDA START Program, also designed to accelerate developmentInterim NGN-401 efficacy data from Cohort 1 remains on track for 4Q:24 NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced second quarter 2024 financial results and highlighted recent corporate updates.“We are pleased that NGN-401 gene therapy for Rett syndrome received RMAT designation, in addition to the recent selection by the U.S. FDA for its START Pilot Program, two programs that provide distinct opportunities for enhanced collaboration and communication with the FDA to accelerate NGN-401’s development,” said Rachel McMinn, Ph.D., Founder and Chief Executive Officer of Neuroge
Show less
Read more
Impact Snapshot
Event Time:
NGNE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NGNE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NGNE alerts
High impacting Neurogene Inc. news events
Weekly update
A roundup of the hottest topics
NGNE
News
- Neurogene Inc. (NASDAQ: NGNE) had its price target lowered by analysts at HC Wainwright from $51.00 to $49.00. They now have a "buy" rating on the stock.MarketBeat
- Neurogene Announces RMAT Designation for NGN-401 Investigational Gene Therapy for Rett SyndromeBusiness Wire
- Neurogene to Participate in BMO Genetic Medicines SummitBusiness Wire
- Neurogene Announces Addition to Russell 3000® IndexBusiness Wire
- Neurogene Inc. (NASDAQ: NGNE) is now covered by analysts at BMO Capital Markets. They set an "outperform" rating and a $65.00 price target on the stock.MarketBeat
NGNE
Earnings
- 8/9/24 - Miss
NGNE
Sec Filings
- 8/9/24 - Form 10-Q
- 8/9/24 - Form 8-K
- 8/7/24 - Form 8-K
- NGNE's page on the SEC website